peptide 3

Peptide 3 is a synthetic, PEGylated dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). Developed by the research group of Richard DiMarchi at Indiana University and subsequently explored by Marcadia Biotech (later acquired by Roche), this peptide was specifically engineered for the treatment of obesity and metabolic syndrome. It is a modified glucagon-based peptide that incorporates unnatural amino acids, including alpha-aminoisobutyric acid (Aib) at position two to confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, and alpha,alpha'-dimethyl imidazole acetic acid (Dmia) at position one to enhance potency. The peptide is site-specifically PEGylated to extend its in vivo half-life and provide a sustained duration of action. Peptide 3 is characterized by a balanced 1:1 potency ratio for the GLP1R and GCGR, a profile designed to maximize weight loss via satiety and increased energy expenditure while preventing the hyperglycemia typically associated with unbalanced glucagon receptor activation.

Other names

balanced GLP-1/GCG co-agonistPEG-Glu-Aib2-Dmia1PEG-Glu-Aib-2-Dmia1PEG-Glu-Aib 2-Dmia1PEGylated GLP-1/glucagon receptor co-agonist